BUZZ-Hims & Hers shares fall as profit margins come under pressure and earnings forecasts are lowered
路透社2026/11/10 10:30November 10 - ** The telemedicine company Hims & Hers Health (stock code: HIMS.N) saw its share price fall by 3.8% in pre-market trading to $22.06
** The company expects (link) annual revenue to be between $3.13 billion and $3.15 billion, compared with previous guidance of $3.10 billion to $3.30 billion
** Adjusted core profit guidance has been revised down from $275 million-$325 million to $257 million-$277 million
** According to data from the London Stock Exchange Group (LSEG), fourth-quarter revenue is expected to be $875 million to $895 million, while market expectations were $953.5 million
** Morningstar stated that as business weakness becomes increasingly apparent, the company’s performance in several areas has been disappointing
** Third-quarter net loss was $33 million, compared with a net profit of $15.8 million in the same period last year
** Quarterly gross margin fell to 57% from 74% a year earlier
** Brokerage Leerink stated: “While several initiatives are underway, it is now urgent to regain margin,” and lowered the price target from $30 to $24
** As of the previous trading day's close, the stock had fallen by 29.3% so far this year
(For the convenience of non-native English speakers, Reuters has automated the translation of its reports into several other languages. As automated translation may contain errors or lack required context, Reuters does not guarantee the accuracy of the automated translation. Automated translation is provided solely for reader convenience. Reuters accepts no liability for any damage or loss caused by the use of automated translation.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Micron Technology removed from Bank of America US 1 List

Bernstein raises Home Depot's target price to $357

On Running raises full-year gross margin forecast, up about 1% in pre-market trading